Literature DB >> 19021003

Chemotherapy-induced Hepatitis B virus reactivation in HbsAg positive cancer patients: a single center experience.

Orhan Onder Eren1, Mehmet Artac, Melih Cem Boruban, Ozlem Yavas, Ugur Arslan, Metin Basaranoglu.   

Abstract

Hepatitis B reactivation due to chemotherapy is a cause of serious morbidity and mortality in some of the patients with cancer. In this study, we retrospectively assessed the prevalence of hepatitis B reactivation among the patients undergoing cytotoxic chemotherapy. We investigated efficacy of lamivudine prophylaxis against hepatitis B reactivation as well.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 19021003     DOI： 10.1007/s12032-008-9133-4

Source DB:  PubMed          Journal:  Med Oncol        ISSN： 1357-0560            Impact factor:   3.064


  34 in total

Review 1.  Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy.

Authors:  Winnie Yeo; Philip J Johnson
Journal:  Hepatology       Date:  2006-02       Impact factor: 17.425

Review 2.  Hepatitis B virus infection.

Authors:  W M Lee
Journal:  N Engl J Med       Date:  1997-12-11       Impact factor: 91.245

Review 3.  Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease.

Authors:  R P Perrillo
Journal:  Gastroenterology       Date:  2001-03       Impact factor: 22.682

4.  Hepatitis B virus carriers in the treatment of malignant lymphoma: an epidemiological study in Japan.

Authors:  K Kumagai; T Takagi; S Nakamura; U Sawada; Y Kura; F Kodama; S Shimano; I Kudoh; H Nakamura; K Sawada; T Ohnoshi
Journal:  Ann Oncol       Date:  1997       Impact factor: 32.976

5.  Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with lymphoid malignancies treated with chemotherapy.

Authors:  G Rossi; A Pelizzari; M Motta; M Puoti
Journal:  Br J Haematol       Date:  2001-10       Impact factor: 6.998

6.  Severe hepatitis related to chemotherapy in hepatitis B virus carriers with hematologic malignancies. Survey in Japan, 1987-1991.

Authors:  Y Nakamura; T Motokura; A Fujita; T Yamashita; E Ogata
Journal:  Cancer       Date:  1996-11-15       Impact factor: 6.860

7.  Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study.

Authors:  A S Lok; R H Liang; E K Chiu; K L Wong; T K Chan; D Todd
Journal:  Gastroenterology       Date:  1991-01       Impact factor: 22.682

Review 8.  Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy.

Authors:  Rohit Loomba; Ayana Rowley; Robert Wesley; T Jake Liang; Jay H Hoofnagle; Frank Pucino; Gyorgy Csako
Journal:  Ann Intern Med       Date:  2008-04-01       Impact factor: 25.391

Review 9.  Lamivudine prevents reactivation of hepatitis B and reduces mortality in immunosuppressed patients: systematic review and meta-analysis.

Authors:  L H Katz; A Fraser; A Gafter-Gvili; L Leibovici; R Tur-Kaspa
Journal:  J Viral Hepat       Date:  2008-02       Impact factor: 3.728

10.  Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy.

Authors:  W Yeo; B Zee; S Zhong; P K S Chan; W-L Wong; W M Ho; K C Lam; P J Johnson
Journal:  Br J Cancer       Date:  2004-04-05       Impact factor: 7.640
View more
  11 in total

1.  Hepatitis B virus reactivation in hepatitis B surface antigen seropositive patients with metastatic non-small cell lung cancer receiving cytotoxic chemotherapy: the efficacy of preemptive lamivudine and identification of risk factors.

Authors:  Gui-Nan Lin; Jie-Wen Peng; Jian-jun Xiao; Dong-Ying Liu; Zhong-Jun Xia
Journal:  Med Oncol       Date:  2014-07-15       Impact factor: 3.064

Review 2.  Hepatitis B virus management to prevent reactivation after chemotherapy: a review.

Authors:  Jessica P Hwang; John M Vierling; Andrew D Zelenetz; Susan C Lackey; Rohit Loomba
Journal:  Support Care Cancer       Date:  2012-08-30       Impact factor: 3.603

Review 3.  Hepatitis B Virus Reactivation and Prophylaxis During Solid Tumor Chemotherapy: A Systematic Review and Meta-analysis.

Authors:  Sonali Paul; Akriti Saxena; Norma Terrin; Kathleen Viveiros; Ethan M Balk; John B Wong
Journal:  Ann Intern Med       Date:  2015-11-24       Impact factor: 25.391

4.  Hepatic sarcoidosis complicating treatment-naive viral hepatitis.

Authors:  Aloysious Aravinthan; William Gelson; Anita Limbu; Rebecca Brais; Paul Richardson
Journal:  World J Hepatol       Date:  2012-12-27

5.  Seroprevalence of hepatitis B and C among oncology patients in Turkey.

Authors:  Sukran Kose; Ali Olmezoglu; Ayhan Gozaydin; Gulfem Ece
Journal:  J Health Popul Nutr       Date:  2011-12       Impact factor: 2.000

6.  Trends in hepatitis B virus screening at the onset of chemotherapy in a large US cancer center.

Authors:  Jessica P Hwang; Michael J Fisch; Anna S-F Lok; Hong Zhang; John M Vierling; Maria E Suarez-Almazor
Journal:  BMC Cancer       Date:  2013-11-09       Impact factor: 4.430

7.  Screening and evaluation of chronic and occult Hepatitis B in chemo - radiotherapy patients with cancer.

Authors:  Mohsen Meidani; Mojtaba Rostami; Simin Hemmati; Farzaneh Ashrafi; Mohammad Gholamnezhad; Maryam Emadi; Rasoul Ghasemian; Mehdi Ahmadian
Journal:  Adv Biomed Res       Date:  2016-05-11

8.  [Reactivation of hepatitis B virus in a patient treated for non-Hodgkin B diffuse large cell lymphoma with rituximab: about a case].

Authors:  Bienvenu Houssou; Romaric Mahutondji Massi; Marième Camara; Hassan Mifdal; Nadia Nourichafi; Saadia Zafad; Bouchra Oukkache
Journal:  Pan Afr Med J       Date:  2015-09-10

Review 9.  Immunosuppression in Patients with Chronic Hepatitis B.

Authors:  Anil Seetharam; Robert Perrillo; Robert Gish
Journal:  Curr Hepatol Rep       Date:  2014-06-21

Review 10.  Systematic review with network meta-analysis: Comparative efficacy of oral nucleos(t)ide analogues for the prevention of chemotherapy-induced hepatitis B virus reactivation.

Authors:  Min-Yue Zhang; Gui-Qi Zhu; Ke-Qing Shi; Ji-Na Zheng; Zhang Cheng; Zhuo-Lin Zou; Hong-Hui Huang; Fang-Yuan Chen; Ming-Hua Zheng
Journal:  Oncotarget       Date:  2016-05-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.